Document Detail

The potential for an improved prognosis with chemotherapy in osteogenic sarcoma.
MedLine Citation:
PMID:  1081438     Owner:  NLM     Status:  MEDLINE    
Effective chemotherapeutic agents administered shortly after definitive primary treatment to patients with osteogenic sarcoma have altered the natural history of the disease. In contrast to past experience, pulmonary metastases fail to develop in the overwhelming majority of patients receiving treatment with chemotherapy. Patients with established pulmonary metastases have also been salvaged. The therapeutic strategy advocated for different categories of patients is outlined. Although chemotherapy involves additional hospitalization and inconvenience, this additional mode of treatment appears to be the only mechanism by which a substantial improvement in survival of osteogenic sarcoma can presently be achieved.
N Jaffe
Related Documents :
16616238 - Soft tissue sarcomas may present with deep vein thrombosis.
22398708 - Clinical recommendation radical trachelectomy for fertility preservation in patients wi...
22443648 - Current surgical therapy for stage iiia (n2) non-small cell lung cancer.
17032558 - Adjuvant therapy for extremity sarcomas.
9919338 - Biomarkers in carcinoma of the cervix: emphasis on tissue-related factors and their pot...
17277528 - Liposarcoma: a clinicopathological study of 73 cases diagnosed at king faisal specialis...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical orthopaedics and related research     Volume:  -     ISSN:  0009-921X     ISO Abbreviation:  Clin. Orthop. Relat. Res.     Publication Date:    1975 Nov-Dec
Date Detail:
Created Date:  1976-02-19     Completed Date:  1976-02-19     Revised Date:  2005-03-03    
Medline Journal Info:
Nlm Unique ID:  0075674     Medline TA:  Clin Orthop Relat Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  111-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Neoplasms / drug therapy*
Dose-Response Relationship, Drug
Doxorubicin / therapeutic use*
Leucovorin / administration & dosage,  therapeutic use*
Lung Neoplasms / drug therapy
Methotrexate / administration & dosage,  therapeutic use*
Neoplasm Metastasis
Osteosarcoma / drug therapy*
Reg. No./Substance:
23214-92-8/Doxorubicin; 58-05-9/Leucovorin; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Potassium influx in the frog atrium during the cardiac cycle.
Next Document:  The lymphocyte response in Hodgkin's disease.